Dyne Therapeutics, Inc.
DYN
$25.70
-$0.26-1.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -25.80% | -23.04% | -40.58% | -43.90% | -60.28% |
| Total Depreciation and Amortization | 13.79% | 17.22% | 22.47% | 21.95% | 17.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.33% | 24.85% | 3.49% | 11.78% | 13.43% |
| Change in Net Operating Assets | -192.23% | -484.44% | 82.54% | -74.63% | 670.98% |
| Cash from Operations | -32.89% | -38.32% | -37.91% | -54.59% | -64.17% |
| Capital Expenditure | -803.50% | -530.13% | -771.63% | -1,440.20% | -82.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.25% | 35.50% | 96.01% | 84.77% | 80.67% |
| Cash from Investing | -62.50% | -43.11% | 85.91% | 71.74% | 79.03% |
| Total Debt Issued | 18.36% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 264.83% | 11.04% | -8.31% | -54.77% | -79.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 170.60% | 39.32% | 9.93% | -42.59% | -66.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 255.57% | 40.48% | 46.23% | -89.66% | -127.96% |